Pharma BD Deal Intelligence

Sanofi SA / Inhibrx Inc.

2024 · Acquisition/Merger · $2.2B · Complete

The Street Said

Strongly positive — critic reaction at announcement

History Says

Largely worked — most objectives met

CALLED IT — OFF BY 9

Full analysis, sources & comparables →

The coverage arc

Mar 31, 2004 Wikipedia Neutral

Sanofi acquired Inhibrx for up to $2.2B for AATD treatment.

May 30, 2024 Sanofi Neutral

Sanofi completes acquisition of Inhibrx, Inc. (closed 2024-05-30); non-101 assets spun out into Inhibrx Biosciences, Inc.

Oct 22, 2025 Sanofi Bullish

Sanofi: efdoralprin alfa (SAR447537, formerly INBRX-101) met all primary and key secondary endpoints in the ElevAATe Phase 2 study in AATD emphysema;…

Source summaries from our enrichment pipeline; follow links for originals.

All 8 sources with sentiment breakdown →

Sanofi acquired Inhibrx for up to $2.2B for AATD treatment.

Key facts

Announced Jan 23, 2024
Closed May 30, 2024
Deal value $2.2B
Deal type Acquisition/Merger
Therapeutic area Rare Disease
Indications Alpha-1 antitrypsin deficiency (AATD) emphysema
Key assets INBRX-101 (efdoralprin alfa / SAR447537)
Mechanism Recombinant human alpha-1 antitrypsin Fc-fusion protein (AAT augmentation; inhibits neutrophil elastase)

Related deals — scored

Deal	Year	Value	Outcome
Sanofi SA / Inhibrx Inc. (this deal)	2024	$2.2B	70
Sanofi SA / Regeneron Pharmaceuticals, Inc.	2007	$1.0B	97
Sanofi SA / Synthelabo S.A.	1998	$11.0B	84
Sanofi SA / Genzyme Corporation	2011	$20.1B	84
Sanofi SA / Amunix Pharmaceuticals Inc.	2021	$1.2B	76
Sanofi SA / Genzyme Corporation	2010	$18.5B	75
Sanofi SA / Translate Bio Inc.	2018	$805M	73

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals

More: 2024 deals · Sanofi SA deals · Rare Disease deals